Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
复制标题
DOI：
10.1136/ard.2008.100834
复制
发表时间：
2008-12-01
影响因子：
27.4
通讯作者：
Weisman, M. H.
中科院分区：
文献类型：
--
作者：
Furst, D. E.;Keystone, E. C.;Weisman, M. H.
与往年一样，考虑使用生物制剂治疗风湿性疾病的共识小组在第10届靶向治疗进展年度研讨会期间举行了会议。该小组由来自欧洲、北美、南美、澳大利亚和亚洲几所大学的风湿病学家组成。制药业从一些公司获得了对年度研讨会本身的支持，但这些公司没有参与关于具体方案或本次会议学术参与者的决定。支助提案国的代表参加了最初的工作组，重点是提供事实资料。提案国没有参加协商一致声明的起草工作。这个共识是从治疗医师的角度准备的。鉴于肿瘤坏死因子o （TNFo）阻滞剂、b细胞特异性药物和白细胞介素1受体拮抗剂（IL1ra）的新数据，更新先前的共识声明是合适的。对共识声明进行注释，以尽可能多地记录支持它的数据的可信度。该注释是Shekelle等人的注释，在附录中进行了描述。我们修改了Shekelle注释，将所有摘要指定为“D类证据”，无论它们是否描述了对照良好的试验，因为研究的细节通常无法在摘要中获得。此外，可能的参考文献的数量已经变得如此之大，以至于有时会包括评论；如果它们包含A类参考，它们将被称为A类证据。参加共识会议的162名风湿病学家和生物科学家来自23个国家，他们因其在使用生物制剂治疗风湿病方面的专业知识而被选中。与会者和参与者的人数有限，因此并非所有可能感兴趣的人都能被邀请。所有参与者都审查了由共同作者制定的一份草案文件，该文件基于对所有与TNF和il - 1阻断剂以及阿巴接受和利妥昔单抗相关的临床发表文章的审查。该草案在小型工作组中进行了讨论。所有与会者在最后一次公开会议上讨论了每一组建议的修订，形成了一份代表这一最新协商一致声明的最后文件。
As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 10th Annual Workshop on Advances in Targeted Therapies. The group consisted of rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia. Pharmaceutical industry support was obtained from a number of companies for the annual workshop itself but these companies had no part in the decisions about the specific programme or about the academic participants at this conference. Representatives of the supporting sponsors participated in the initial working groups with emphasis on supplying factual information. The sponsors did not participate in the drafting of the consensus statement.This consensus was prepared from the perspective of the treating physician. In view of the new data for tumour necrosis factor o (TNFo) blocking agents, B-cell-specific agents and interleukin 1 receptor antagonists (IL1ra), an update of the previous consensus statement is appropriate. The consensus statement is annotated to document the credibility of the data supporting it as much as possible. This annotation is that of Shekelle et al and is described in an appendix. We have modified the Shekelle annotation by designating all abstracts as ‘‘category D evidence’’, whether they describe wellcontrolled trials or not, as details of the study were often not available in the abstracts. Further, the number of possible references has become so large, that reviews are sometimes included; if they contain category A references, they will be referred to as category A evidence. The 162 rheumatologists and bioscientists who attended the consensus conference were from 23 countries, and were selected for their expertise in the use of biological agents for the treatment of rheumatic diseases. The number of attendees and participants was limited so that not everyone who might have been interested could be invited. All participants reviewed a draft document developed by the coauthors, based on a review of all relevant clinical published articles relating to TNF and IL1 blocking agents, as well as abatacept and rituximab. The draft was discussed in small working groups. The revisions suggested by each group were discussed by all participants in a final open session and this led to a final document, representing this updated consensus statement.